common.study.topics.clinical

Ultralow Dose PAH Binary Mixture Study

common.study.values.description

Ultralow Dose PAH Binary Mixture Study

Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - [14C]-benzo[a]pyrene

Oral micro-dose (50 ng) (5.4 nCi)

Drug - [14C]-benzo[a]pyrene plus phenanthrene

Oral micro-dose of 50 ng (5.4 nCi) [14C]-benzo[a]pyrene plus 1250 ng phenanthrene

participant.views.study.view.additional

participant.views.study.view.scientific-title

Ultralow Dose PAH Binary Mixture Study

common.study.values.clinical-trial-id

NCT03631667

participant.views.study.view.id

e1wrVb